Orphan Synergy Europe - Pharma – Trademark Portfolio
Entity Type: 99
Orphan Synergy Europe - Pharma holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include OSE IMMUNOTHERAPEUTICS. The owner is based in Paris.
La Pépinière Paris Santé Cochin
29 Bis Rue du Faubourg Saint-Jacques
Paris 75014 , FR
Showing of trademarks Trademarks
Trademark Classifications
Orphan Synergy Europe - Pharma's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Orphan Synergy Europe - Pharma have?
Orphan Synergy Europe - Pharma has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 cancelled.
What trademark classes does Orphan Synergy Europe - Pharma file in?
Orphan Synergy Europe - Pharma files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Orphan Synergy Europe - Pharma's most well-known trademarks?
Orphan Synergy Europe - Pharma's registered trademark portfolio includes well-known marks such as OSE IMMUNOTHERAPEUTICS. These are among 1 currently registered trademark in the portfolio.
What is Orphan Synergy Europe - Pharma's trademark registration success rate?
Orphan Synergy Europe - Pharma has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.